학술논문

COVID-19 in patients with autoimmune diseases: characteristics and outcomes in a multinational network of cohorts across three countries
Document Type
article
Source
Rheumatology. 60(SI)
Subject
Infectious Diseases
Lung
Emerging Infectious Diseases
Pneumonia & Influenza
Clinical Research
Influenza
Autoimmune Disease
Cardiovascular
Good Health and Well Being
Adult
Aged
Aged
80 and over
Autoimmune Diseases
COVID-19
Cohort Studies
Female
Hospitalization
Humans
Influenza
Human
Male
Middle Aged
Prevalence
Prognosis
Republic of Korea
SARS-CoV-2
Spain
United States
Young Adult
autoimmune condition
mortality
hospitalization
open science
Observational Health Data Sciences and Informatics
Observational Medical Outcomes Partnership
Clinical Sciences
Immunology
Public Health and Health Services
Arthritis & Rheumatology
Language
Abstract
ObjectivePatients with autoimmune diseases were advised to shield to avoid coronavirus disease 2019 (COVID-19), but information on their prognosis is lacking. We characterized 30-day outcomes and mortality after hospitalization with COVID-19 among patients with prevalent autoimmune diseases, and compared outcomes after hospital admissions among similar patients with seasonal influenza.MethodsA multinational network cohort study was conducted using electronic health records data from Columbia University Irving Medical Center [USA, Optum (USA), Department of Veterans Affairs (USA), Information System for Research in Primary Care-Hospitalization Linked Data (Spain) and claims data from IQVIA Open Claims (USA) and Health Insurance and Review Assessment (South Korea). All patients with prevalent autoimmune diseases, diagnosed and/or hospitalized between January and June 2020 with COVID-19, and similar patients hospitalized with influenza in 2017-18 were included. Outcomes were death and complications within 30 days of hospitalization.ResultsWe studied 133 589 patients diagnosed and 48 418 hospitalized with COVID-19 with prevalent autoimmune diseases. Most patients were female, aged ≥50 years with previous comorbidities. The prevalence of hypertension (45.5-93.2%), chronic kidney disease (14.0-52.7%) and heart disease (29.0-83.8%) was higher in hospitalized vs diagnosed patients with COVID-19. Compared with 70 660 hospitalized with influenza, those admitted with COVID-19 had more respiratory complications including pneumonia and acute respiratory distress syndrome, and higher 30-day mortality (2.2-4.3% vs 6.32-24.6%).ConclusionCompared with influenza, COVID-19 is a more severe disease, leading to more complications and higher mortality.